■为了比较效果,成本,世界卫生组织(WHO)推荐的四种方案在华东地区用于利福平耐药/耐多药结核病(RR/MDR-TB)治疗的安全性。
■我们在江苏省2020年至2022年的RR/MDR患者中进行了一项队列研究。治疗成功率,成本,并比较药物不良反应发生率。
■在2020年至2022年之间,253名RR/MDR-TB患者被纳入研究。37(14.62%),76(30.04%),74(29.25%),66例(26.09%)患者接受短期治疗,新的长期口服治疗方案,新的长期注射方案,传统的长期治疗方案,分别。短期方案治疗的患者治疗成功率最高(75.68%),传统长期方案治疗的患者治疗成功率最低(60.61%)。每个有利结果的估计平均成本为142.61万元人民币(人民币),短期方案在四种方案中成本最低(88.51万元人民币与174.24万元人民币,144.00万元人民币,和134.98万元人民币)。短期方案的成本效益比递增,新的长期口服方案,与传统长期注射方案相比,新的长期注射方案为-3083.04、6040.09和819.68CNY。
■对于中国符合短期治疗标准的RR/MDR-TB患者,在世卫组织推荐的4种方案中,短期方案被证明是最具成本效益的.对于中国不符合短期治疗标准的RR/MDR-TB患者,新的长期注射方案比其余两种方案更具成本效益.
这是第一项评估有效性的研究,成本,和世界卫生组织推荐的四种治疗方案在中国用于RR/MDR-TB治疗的安全性。对于中国符合短期治疗方案标准的RR/MDR-TB患者,在世卫组织推荐的4种方案中,短期方案被证明是最具成本效益的.
UNASSIGNED: To compare the effectiveness, cost, and safety of four regimens recommended by the World Health Organization (WHO) for rifampicin resistance/multidrug-resistance tuberculosis (RR/MDR-TB) Treatment in Eastern
China.
UNASSIGNED: We performed a cohort study among patients with RR/MDR between 2020 and 2022 in Jiangsu Province. The treatment success rate, cost, and drug adverse reaction rate were compared.
UNASSIGNED: Between 2020 and 2022, 253 RR/MDR-TB patients were enrolled in the study. 37 (14.62%), 76 (30.04%), 74 (29.25%), and 66 (26.09%) patients had the short-term regimens, the new long-term oral regimens, the new long-term injectable regimens, and the traditional long-term regimens, respectively. The treatment success rate was the highest among patients treated with the short-term regimen (75.68%) and was the lowest among patients treated with the traditional long-term regimens (60.61%). The estimated mean cost per favorable outcome was 142.61 thousand Chinese Yuan (CNY), and the short-term regimens showed the lowest cost in the four regimes (88.51 thousand CNY vs. 174.24 thousand CNY, 144.00 thousand CNY, and 134.98 thousand CNY). Incremental cost-effectiveness ratios of the short-term regimens, the new long-term oral regimen, and the new long-term injectable regimens were -3083.04, 6040.09, and 819.68 CNY compared to the traditional long-term regimens.
UNASSIGNED: For RR/MDR-TB patients in
China who meet the criteria for short-term regimens, the short-term regimens were proven to be the most cost-effective of the four regimens recommended by WHO. For RR/MDR-TB patients in
China who don\'t meet the criteria for short-term regimens, the new long-term injectable regimens are more cost-effective than the remaining two regimens.
This is the first study to evaluate the effectiveness, cost, and safety of four regimens recommended by the WHO for RR/MDR-TB treatment in China.For RR/MDR-TB patients in
China who meet the criteria for the short-term regimens, the short-term regimens were proven to be the most cost-effective of the four regimens recommended by WHO.